FindTrial
Sign In

Efficacy of Vonoprazan for sleeping dysorder caused by gastroesophageal reflux disease (GERD) symptoms.

Efficacy of Vonoprazan for sleeping dysorder caused by gastroesophageal reflux disease (GERD) symptoms. - Efficacy of Vonoprazan for sleeping dysorder caused by GERD symptoms.

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000021521
Enrollment
20
Registered
2016-03-18
Start date
2016-04-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroesophageal reflux disease (GERD)

Interventions

Administration of Vonoprazan 20mg/day for 8 weeks p.o., continued by 10mg/day for 8 weeks p.o.

Sponsors

Machida municipal hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: An outpatient who is diagnosed as reflux esophagitis LA grade A-D by EGD, and who has spleeping dysorder caused by GERD. No history of recent administration of PPI for 8 weeks.

Exclusion criteria

Exclusion criteria: Having oral medicine which may effect gastrointestinal motility. Equivalent to contraindications of the package insert of Vonaprazan. No history of upper gastrointestinal operation.

Design outcomes

Primary

MeasureTime frame
An improvement of the sleeping dysorder caused by GERD, in 4, 8, 12 and 16 weeks after start of administration.—

Countries

Japan

Contacts

Public ContactMotoyoshi Izumi

Machida municipal hospital Department of Gastroenterology

m.izumi@machida-city-hp.jp042-722-2230

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026